{"id":949413,"date":"2026-04-07T09:31:46","date_gmt":"2026-04-07T13:31:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\/"},"modified":"2026-04-07T09:31:46","modified_gmt":"2026-04-07T13:31:46","slug":"inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\/","title":{"rendered":"Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension"},"content":{"rendered":"
\n

WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (\u201cInhibikase\u201d or \u201cCompany\u201d), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (\u201cPAH\u201d), announced today that the first patient has been enrolled in the Company\u2019s pivotal Phase 3 study IMPROVE-PAH (I<\/strong>KT-001 for M<\/strong>easuring P<\/strong>ulmonary Vascular R<\/strong>esistance and O<\/strong>utcome V<\/strong>ariables in a Phase 3 E<\/strong>valuation of PAH; <\/strong>NCT07365332<\/a>).<\/p>\n

\u201cEnrollment of the first patient in our IMPROVE-PAH trial is a major milestone for Inhibikase, and the result of many months of work to optimize the IKT-001 study plan to permit a single pivotal global study and significantly accelerate the timeline to potential NDA filing,\u201d said Mark Iwicki, Chief Executive Officer of Inhibikase. IKT-001 is a novel oral prodrug of imatinib mesylate designed to reduce gastrointestinal (\u201cGI\u201d) side effects commonly observed with imatinib. Under the revised pivotal Phase 3 design, as confirmed in the written responses received from the FDA, Inhibikase has adopted an adaptive study design and a 12-week dose-titration phase to allow for optimized dosing. With over two decades of imatinib clinical experience, together with the potential GI benefits of IKT-001, Inhibikase believes IMPROVE-PAH has a high probability of success.<\/p>\n

The global IMPROVE-PAH trial is a two-part adaptive Phase 3 study.\u00a0\u00a0 Part A of IMPROVE-PAH is a double blind, placebo-controlled study in approximately 140 patients with a primary endpoint of change in Pulmonary Vascular Resistance (\u201cPVR\u201d) at Week 24. Part B of IMPROVE-PAH seamlessly begins following the last patient in Part A being enrolled and adopts an identical format to Part A, except the primary endpoint will be change in 6-minute walk distance (\u201c6MWD\u201d) at Week 24 in approximately 346 patients. The Company believes this Phase 3 study design has important advantages including permitting a 12-week dose-titration phase designed to get patients to the highest tolerable dose of IKT-001, as well as uninterrupted enrollment between Part A and Part B. The Phase 3 study protocol also permits a sample size re-estimation for Part B based on Part A findings, if necessary. IMPROVE-PAH is expected to be conducted in up to approximately 180 sites around the world.<\/p>\n

“The Phase 3 IMPRES study demonstrated that imatinib may improve key parameters associated with PAH, including exercise capacity and hemodynamics,\u201d said Dr. Harrison Farber, Co-director of Pulmonary Hypertension Center and Director of the Pulmonary Embolism Response Team (PERT), Tufts Medical Center. \u201cNow, the Phase 3 IMPROVE-PAH study will help evaluate both hemodynamic and functional improvements, as well as key measures of disease progression, such as time to clinical worsening. Despite the availability of multiple therapies, many patients with PAH continue to experience disease progression, so I am always excited about the potential for a novel antiproliferative agent for the treatment of PAH.”\u00a0\u00a0<\/p>\n

“For patients living with PAH disease progression remains a daily reality even with the therapies we have available today,” said Dr. J. Wesley McConnell, M.D., Director of Norton Pulmonary Specialists Pulmonary Hypertension Center in Louisville, Kentucky. “The IMPROVE-PAH trial represents a meaningful step forward because the trial is designed to capture the outcomes that matter most to patients and clinicians alike. I am proud to be part of this program and optimistic about what it could mean for the future of PAH care\u201d.<\/p>\n

\n About Inhibikase (www.inhibikase.com) <\/strong>\n <\/p>\n

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (\u201cPAH\u201d), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as \u201cc-Kit\u201d has been implicated. Our lead product candidate\u00a0is IKT-001, a prodrug of imatinib mesylate (\u201cimatinib\u201d), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans.\u00a0Our single pivotal Phase 3 clinical study in PAH in approximately 180 sites around the world, named IMPROVE-PAH (I<\/strong>KT-001 for M<\/strong>easuring P<\/strong>ulmonary Vascular R<\/strong>esistance and O<\/strong>utcome V<\/strong>ariables in a Phase 3 E<\/strong>valuation of PAH<\/strong>), is actively enrolling patients.<\/p>\n

\n Social Media Disclaimer<\/strong>\n <\/p>\n

Investors and others should note that the Company announces material financial information to investors using its investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use LinkedIn\u00a0and\u00a0YouTube\u00a0as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as \u201cbelieves,\u201d \u201cexpects,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201canticipates,\u201d \u201cplans,\u201d or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements that express the Company\u2019s intentions, beliefs, expectations, strategies, predictions or any other statements related to the potential effects of IKT-001, the advancement of the Company\u2019s global pivotal Phase 3 clinical study of IKT-001 in PAH, including the timing, design, enrollment, conduct and results of the IMPROVE-PAH study and related regulatory submissions, including the potential for NDA submission, the Company\u2019s beliefs regarding the potential advantages of the Phase 3 clinical study of IKT-001, or future events or conditions. These forward-looking statements are based on Inhibikase\u2019s current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase\u2019s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include our ability to commence and execute a Phase 3 study to evaluate IKT-001 as a treatment for PAH, as well as such other factors that are included in our periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.<\/p>\n

\n Contacts:<\/strong>\n <\/p>\n

\n Investor Relations:<\/em>
\n
Michael Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (\u201cInhibikase\u201d or \u201cCompany\u201d), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (\u201cPAH\u201d), announced today that the first patient has been enrolled in the Company\u2019s pivotal Phase 3 study IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH; NCT07365332). \u201cEnrollment of the first patient in our IMPROVE-PAH trial is a major milestone for Inhibikase, and the result of many months of work to optimize the IKT-001 study plan to permit a single pivotal global study and significantly accelerate the timeline to potential NDA filing,\u201d said Mark Iwicki, Chief Executive Officer of Inhibikase. IKT-001 is a novel oral prodrug … <\/p>\n

Continue reading “Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-949413","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nInhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (\u201cInhibikase\u201d or \u201cCompany\u201d), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (\u201cPAH\u201d), announced today that the first patient has been enrolled in the Company\u2019s pivotal Phase 3 study IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH; NCT07365332). \u201cEnrollment of the first patient in our IMPROVE-PAH trial is a major milestone for Inhibikase, and the result of many months of work to optimize the IKT-001 study plan to permit a single pivotal global study and significantly accelerate the timeline to potential NDA filing,\u201d said Mark Iwicki, Chief Executive Officer of Inhibikase. IKT-001 is a novel oral prodrug … Continue reading "Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-07T13:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDY5NCM3NTIxMzYwIzIxNTY3NjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension\",\"datePublished\":\"2026-04-07T13:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\\\/\"},\"wordCount\":1072,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NDY5NCM3NTIxMzYwIzIxNTY3NjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\\\/\",\"name\":\"Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NDY5NCM3NTIxMzYwIzIxNTY3NjI=\",\"datePublished\":\"2026-04-07T13:31:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NDY5NCM3NTIxMzYwIzIxNTY3NjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NDY5NCM3NTIxMzYwIzIxNTY3NjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\/","og_locale":"en_US","og_type":"article","og_title":"Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension - Market Newsdesk","og_description":"WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (\u201cInhibikase\u201d or \u201cCompany\u201d), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (\u201cPAH\u201d), announced today that the first patient has been enrolled in the Company\u2019s pivotal Phase 3 study IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH; NCT07365332). \u201cEnrollment of the first patient in our IMPROVE-PAH trial is a major milestone for Inhibikase, and the result of many months of work to optimize the IKT-001 study plan to permit a single pivotal global study and significantly accelerate the timeline to potential NDA filing,\u201d said Mark Iwicki, Chief Executive Officer of Inhibikase. IKT-001 is a novel oral prodrug … Continue reading \"Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-07T13:31:46+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDY5NCM3NTIxMzYwIzIxNTY3NjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension","datePublished":"2026-04-07T13:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\/"},"wordCount":1072,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDY5NCM3NTIxMzYwIzIxNTY3NjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\/","name":"Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDY5NCM3NTIxMzYwIzIxNTY3NjI=","datePublished":"2026-04-07T13:31:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDY5NCM3NTIxMzYwIzIxNTY3NjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDY5NCM3NTIxMzYwIzIxNTY3NjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949413","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=949413"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949413\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=949413"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=949413"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=949413"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}